SCHEMBL6433736

SCHEMBL6433736

Cc1c(C)c2c(c(C)c1O)CCC(C)(CN1CCN(c3cc(N4CCCC4)nc(N4CCCC4)n3)CC1)O2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 1.00
CYP2C9 P11712 2/20 1.00
CYP3A4 P08684 2/20 1.00
TSHR P16473 2/20 1.00
TP53 P04637 1/20 1.00
ALOX15 P16050 1/20 1.00
NFKB1 P19838 1/20 1.00
THPO P40225 1/20 1.00
HIF1A Q16665 1/20 1.00
LCK P06239 1/20 1.00
FYN P06241 1/20 1.00
ADORA3 P0DMS8 1/20 1.00
DRD2 P14416 1/20 1.00
ADRA1D P25100 1/20 1.00
MAPK3 P27361 1/20 1.00
HTR2C P28335 1/20 1.00
MC4R P32245 1/20 1.00
HRH1 P35367 1/20 1.00
OPRM1 P35372 1/20 1.00
DRD3 P35462 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3092488 0.99 LMNA (1.00) USP2CYP2C9CYP3A4TSHRTP53
Hydrochloric Acid SCHEMBL29377695 0.99 LMNA (1.00) USP2CYP2C9CYP3A4TSHRTP53
Hydrochloric Acid SCHEMBL29435423 0.99 LMNA (1.00) USP2CYP2C9CYP3A4TSHRTP53
Citric Acid SCHEMBL9285899 0.89 CYP3A4 (0.80) USP2CYP2C9CYP3A4TSHRTP53
SCHEMBL9688266 0.89 USP2 (0.81) USP2CYP2C9CYP3A4TSHRTP53
SCHEMBL9702365 0.85 CYP3A4 (0.74) USP2CYP2C9CYP3A4TSHRTP53
SCHEMBL9712224 0.83 USP2 (0.71) USP2CYP2C9CYP3A4TSHRTP53
SCHEMBL9690398 0.83 USP2 (0.71) USP2CYP2C9CYP3A4TSHRTP53
SCHEMBL9689851 0.82 CYP3A4 (0.69) USP2CYP2C9CYP3A4TSHRTP53
SCHEMBL10366298 0.82 USP2 (0.68) USP2CYP2C9CYP3A4TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0784471-B1 MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS HIV DIAGNOSTICS INC (US) 2005-06-08 EP claimed
EP-0792153-B1 COMPOSITIONS CONTAINING LAZAROIDS AND THEIR USE FOR PREVENTING ADHESIONS UNIV SOUTHERN CALIFORNIA (US) 2002-03-27 EP claimed
EP-0792153-A1 COMPOSITIONS CONTAINING LAZAROIDS AND THEIR USE FOR PREVENTING ADHESIONS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 1997-09-03 EP claimed
US-5614515-A PREVENTING TISSUE ADHESION AFTER SURGERY UNIVERSITY OF SOUTHERN CALIFORNIA (US) 1997-03-25 US claimed
WO-1996015795-A1 COMPOSITIONS CONTAINING LAZAROIDS AND THEIR USE FOR PREVENTING ADHESIONS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 1996-05-30 WO claimed
WO-1994012185-A1 COMBINATION OF A CALCIUM CHANNEL BLOCKER AND AN ANTIOXYDANT FOR TREATING ISCHEMIC DISEASES THE UPJOHN COMPANY (US) 1994-06-09 WO claimed
WO-1992018089-A2 USE OF STEROIDAL AND NON-STEROIDAL AMINES TO SENSITIZE MULTIDRUG-RESISTANT CELLS THE UPJOHN COMPANY (US) 1992-10-29 WO claimed
EP-0487510-A1 Pharmaceutically active amines THE UPJOHN COMPANY (US) 1992-05-27 EP claimed
EP-0358676-A1 PHARMACEUTICALLY ACTIVE AMINES THE UPJOHN COMPANY (US) 1990-03-21 EP claimed
EP-0293078-A1 Pharmaceutically active amines THE UPJOHN COMPANY (US) 1988-11-30 EP claimed
WO-1988008424-A1 PHARMACEUTICALLY ACTIVE AMINES THE UPJOHN COMPANY (US) 1988-11-03 WO claimed
EP-4709405-A2 FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS Alume Biosciences, Inc. (US) 2026-03-18 EP disclosed
US-12533425-B2 Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery ALUME BIOSCIENCES, INC. (US) 2026-01-27 US disclosed
EP-4484952-A2 OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY The Regents of the University of California (US) 2025-01-01 EP disclosed
WO-2024233683-A2 FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS ALUME BIOSCIENCES, INC. (US) 2024-11-14 WO disclosed
US-5120843-A Nervous system disorders UPJOHN (US) 1992-06-09 US disclosed
EP-0487510-A1 Pharmaceutically active amines THE UPJOHN COMPANY (US) 1992-05-27 EP disclosed
EP-0358676-A1 PHARMACEUTICALLY ACTIVE AMINES THE UPJOHN COMPANY (US) 1990-03-21 EP disclosed
EP-0293078-A1 Pharmaceutically active amines THE UPJOHN COMPANY (US) 1988-11-30 EP disclosed
WO-1988008424-A1 PHARMACEUTICALLY ACTIVE AMINES THE UPJOHN COMPANY (US) 1988-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12533425-B2 Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery NGLY1, VGF, GAP43 USP2 965/4885CYP2C9 4670/4885CYP3A4 4828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.